A study from Columbia University suggests some health advocacy groups fail to disclose funding from drug manufacturers, according to a New York Times report.
The study examined the relationship between the drug maker Eli Lilly and 161 health advocacy groups who collected payments from the company. Comparing Eli Lilly's payment disclosure with the groups' disclosures, the study found that only 25 percent of the groups acknowledged Lilly's support on their public websites, and only 10 percent disclosed Lilly as the sponsor of a specific grant.
The researchers recommended expanding the Physician Payment Sunshine Act to require drug and medical device companies to report these payments. They also said federal tax regulations should force nonprofit health advocacy groups to list industry donors and sums on their tax returns.
Read the New York Times report on health advocacy groups.
Read more on drug manufacturers:
-6 Predictions on Device Market Growth in the Next Five Years
-Study: Extending Clinical Data Could Raise Drug Costs, Life Expectancy
The study examined the relationship between the drug maker Eli Lilly and 161 health advocacy groups who collected payments from the company. Comparing Eli Lilly's payment disclosure with the groups' disclosures, the study found that only 25 percent of the groups acknowledged Lilly's support on their public websites, and only 10 percent disclosed Lilly as the sponsor of a specific grant.
The researchers recommended expanding the Physician Payment Sunshine Act to require drug and medical device companies to report these payments. They also said federal tax regulations should force nonprofit health advocacy groups to list industry donors and sums on their tax returns.
Read the New York Times report on health advocacy groups.
Read more on drug manufacturers:
-6 Predictions on Device Market Growth in the Next Five Years
-Study: Extending Clinical Data Could Raise Drug Costs, Life Expectancy